TY - JOUR
T1 - Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells
AU - Verneris, Michael R
AU - Arshi, Arash
AU - Edinger, Matthias
AU - Kornacker, Martin
AU - Natkunam, Yaso
AU - Karami, Mobin
AU - Cao, Yu An
AU - Marina, Neyssa
AU - Contag, Christopher H.
AU - Negrin, Robert S.
PY - 2005/6/15
Y1 - 2005/6/15
N2 - Purpose: To identify novel treatments for pediatric solid tumors and/or for malignancies with low-level Her2/neu expression. Experimental Design: Using fluorescence-activated cell sorting and immunohistochemistry, Her2/neu expression was determined on cell lines derived from Ewing's family tumors (EFT) and neuroblastoma. Sensitivity to trastuzumab treatment was investigated using an in vitro proliferation assay. Cytotoxicity against EFT cell lines was done with either freshly isolated or ex vivo activated and expanded T cells (cytokine-induced killer cells, CIK cells), with or without addition of a CD3xHer2/neu bispecific antibody. The effects of either trastuzumab, CIK cells alone, or CD3xHer2/neu bispecific antibody redirected CIK cells was determined using a SCID/hu model of EFTs and serial, noninvasive bioluminescent imaging. Results: EFT cell lines express 5- to 10-fold lower levels of her2/neu than either breast (BT-474) or ovarian (SK-OV-3) cell lines. Treatment of EFT cell lines with trastuzumab did not induce growth inhibition either in vitro or in vivo. In contrast, Her2/neu could be used to redirect CIK cell to mediate cytotoxicity against EFTs both in vitro and in vivo (using two different treatment schemas). Conclusions: CD3xHer2/neu bispecific antibody and CIK cells may be a suitable approach to treat malignancies with low-level Her2/neu expression not responsive to trastuzumab.
AB - Purpose: To identify novel treatments for pediatric solid tumors and/or for malignancies with low-level Her2/neu expression. Experimental Design: Using fluorescence-activated cell sorting and immunohistochemistry, Her2/neu expression was determined on cell lines derived from Ewing's family tumors (EFT) and neuroblastoma. Sensitivity to trastuzumab treatment was investigated using an in vitro proliferation assay. Cytotoxicity against EFT cell lines was done with either freshly isolated or ex vivo activated and expanded T cells (cytokine-induced killer cells, CIK cells), with or without addition of a CD3xHer2/neu bispecific antibody. The effects of either trastuzumab, CIK cells alone, or CD3xHer2/neu bispecific antibody redirected CIK cells was determined using a SCID/hu model of EFTs and serial, noninvasive bioluminescent imaging. Results: EFT cell lines express 5- to 10-fold lower levels of her2/neu than either breast (BT-474) or ovarian (SK-OV-3) cell lines. Treatment of EFT cell lines with trastuzumab did not induce growth inhibition either in vitro or in vivo. In contrast, Her2/neu could be used to redirect CIK cell to mediate cytotoxicity against EFTs both in vitro and in vivo (using two different treatment schemas). Conclusions: CD3xHer2/neu bispecific antibody and CIK cells may be a suitable approach to treat malignancies with low-level Her2/neu expression not responsive to trastuzumab.
UR - http://www.scopus.com/inward/record.url?scp=20444503896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444503896&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-0157
DO - 10.1158/1078-0432.CCR-05-0157
M3 - Article
C2 - 15958642
AN - SCOPUS:20444503896
SN - 1078-0432
VL - 11
SP - 4561
EP - 4570
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -